This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Sana Biotechnology has a new $50 million tool in its toolbox. Beam may also receive additional payments, for instance upon the achievement of development and sales milestones. Sana aims to develop therapeutics for conditions as diverse as cancer, diabetes and cardiovascular disorders. Sana CEO and president Steve Harr.
Levitate Bio’s CEO Sam DeLuca, left, and Karen Khar, executive vice president of sales and business development. The University of Washington has issued more than 60,000 non-commercial licenses to Rosetta users, and more than 200 licenses to commercial organizations. Tech companies are really good at what they do.
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax Photo).
To make a profit, yes, but also to support the development of technologies needed to sustain settlements on the Red Planet. “Those inventions — as it were, IP as exports from Mars — will be one of the main economic supports of the Mars city-state,” Zubrin said.
based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a $600 million upfront payment and make a $1 billion equity investment to continue development of treatments for breast cancer. billion if development milestones are met, and another $1.75 Merck will own about 2.9
Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than $900 million. Immusoft CEO Sean Ainsworth. Immusoft Photo). Immusoft closed a $33 million Series B round last year, noted FierceBiotech.
Washington State University assistant professor and Appiture Biotechnologies co-founder Georgina Lynch. Hojah received funding from Simpson and other backers to launch his eight-employee startup developing assistive technologies for people with multiple sclerosis and other conditions. WSU Photo).
The publicly traded Seattle biotech company hired investment bank SVB Securities to review potential alternatives including a sale, merger, asset divestiture or licensing. “It Neoleukin shifted its focus to developing other protein therapeutics.
AltPep is developing tools and treatments for diseases caused by amyloid proteins that are incorrectly folded and create harmful deposits. The UW has licensed the exclusive rights of this intellectual property to the startup. Another Seattle-area biotech startup, Athira Pharma, is also developing treatments for Alzheimer’s.
On March 21, CEO Jensen Huang (pictured) told attendees at the company’s online-only developer conference, GTC 2023, about a string of new services Nvidia hopes enterprises will use to train and run their own generative AI models. It named biotechnology company Amgen as one of the first users of the service.
Founded in 2018, Vouched helps companies verify the identity of customers and users by examining driver’s licenses and other forms of identification. Sana Photo) — Dhaval Patel joined Sana Biotechnology as executive vice president and chief scientific officer. It can provide fraud detection of a person in real-time.
The investment firm’s team includes senior associate Dasom (Christine) Yoo , former Fred Hutchinson Cancer Research Center business development manager. Kawas co-founded Athira (originally M3 Biotechnology) in 2011. Papers with altered images were cited in an earlier patent licensed by the company from WSU.
Juno veterans went on to start or fill leadership positions at Sana Biotechnology, Lyell Immunopharma, Umoja Biopharma, Shape Therapeutics, GentiBio, Eliem Therapeutics, Genemod, Century Therapeutics, Silverback Therapeutics, Tune Therapeutics, Affini-T Therapeutics, and others. Photo courtesy of William Canestaro). Fred Hutch owned 4.6%
He develops tools to help understand massive-scale genomic and biomedical data and has helped generate online learning programs that have enrolled more than 8 million people. I think there’s a lot of room for creativity, especially within the data, machine learning and AI space at the interface between biotechnology and data science.
Founded in 2010, Leafly’s online marketplace lets customers shop and select cannabis products from licensed retailers. Leafly is among a group of Seattle-area companies going public via the SPAC route, joining a list that includes Rover, Nautilus Biotechnology, and Getty Images. Shares were up about 7% as of Monday afternoon.
Founded in 2002 as Seattle Genetics, the company is a pioneer in the development of antibody-drug conjugates (ADCs), a class of drugs that zeros in on cells using an antibody and delivers a toxin to them. .” Seagen has been “incredibly productive,” said David Miller , a consultant for Seattle area biopharma companies.
So you buy a processing unit design from somebody like Arm in the UK, who is very popular, and then maybe you need the USB interface, so you get a USB IP block, which you license. So you decide, “I want to build a controller chip.” Moderna, for example, had been working on it for a decade with $1 billion of private capital invested.
But even more important is to think about the technologies you are developing for the next long phase, which is about Resilience for the future. And I’ll earn my A-class license on iRacing…. The tech industry has contributed to polarization through the various social media platforms that we developed. The tech backlash is real.
We organize all of the trending information in your field so you don't have to. Join 83,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content